keyword
MENU ▼
Read by QxMD icon Read
search

Integrative medicine cancer

keyword
https://www.readbyqxmd.com/read/29774410/correction-to-breast-cancer-patients-satisfaction-with-individual-therapy-goals-and-treatment-in-a-standardized-integrative-medicine-consultancy-service
#1
Carolin C Hack, Sophia Antoniadis, Janina Hackl, Hanna Langemann, Judith Schwitulla, Peter A Fasching, Matthias W Beckmann, Anna-Katharin Theuser
In the original version of this article contained an error in figure 1. It was provided in German.
May 17, 2018: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/29774075/plectin-targeted-liposomes-enhance-the-therapeutic-efficacy-of-a-parp-inhibitor-in-the-treatment-of-ovarian-cancer
#2
Siva Sai Krishna Dasa, Galina Diakova, Ryo Suzuki, Anne M Mills, Michael F Gutknecht, Alexander L Klibanov, Jill K Slack-Davis, Kimberly A Kelly
Advances in genomics and proteomics drive precision medicine by providing actionable genetic alterations and molecularly targeted therapies, respectively. While genomic analysis and medicinal chemistry have advanced patient stratification with treatments tailored to the genetic profile of a patient's tumor, proteomic targeting has the potential to enhance the therapeutic index of drugs like poly(ADP-ribose) polymerase (PARP) inhibitors. PARP inhibitors in breast and ovarian cancer patients with BRCA1/2 mutations have shown promise...
2018: Theranostics
https://www.readbyqxmd.com/read/29764369/vareporter-variant-reporter-for-cancer-research-of-massive-parallel-sequencing
#3
Po-Jung Huang, Chi-Ching Lee, Ling-Ya Chiu, Kuo-Yang Huang, Yuan-Ming Yeh, Chia-Yu Yang, Cheng-Hsun Chiu, Petrus Tang
BACKGROUND: High throughput sequencing technologies have been an increasingly critical aspect of precision medicine owing to a better identification of disease targets, which contributes to improved health care cost and clinical outcomes. In particular, disease-oriented targeted enrichment sequencing is becoming a widely-accepted application for diagnostic purposes, which can interrogate known diagnostic variants as well as identify novel biomarkers from panels of entire human coding exome or disease-associated genes...
May 9, 2018: BMC Genomics
https://www.readbyqxmd.com/read/29759193/highly-sensitive-detection-and-mutational-analysis-of-lung-cancer-circulating-tumor-cells-using-integrated-combined-immunomagnetic-beads-with-a-droplet-digital-pcr-chip
#4
Wanlei Gao, Ting Huang, Haojun Yuan, Jun Yang, Qinghui Jin, Chunping Jia, Guoxin Mao, Jianlong Zhao
Circulating tumor cells (CTCs) have become an important biomarker for liquid biopsy to monitor tumor progression and indicate response to therapies. Many epithelial cellular adhesion molecule (EpCAM) dependent CTC isolation methods have been developed, which have a limitation for low EpCAM expressed tumor cells. In an effort to overcome these drawbacks, we developed combined immunomagnetic beads (EpCAM, Mucin1 and epidermal growth factor receptor) to sensitively isolate CTCs for immunofluorescence analysis and genetic characterization...
August 1, 2018: Talanta
https://www.readbyqxmd.com/read/29755917/sharing-is-caring-minimizing-the-disruption-with-palliative-care
#5
EDITORIAL
Abd Moain Abu Dabrh, Robert P Shannon, Richard J Presutti
There is an upward trend incidence of multiple chronic life-limiting conditions with a well-documented associated impact on patients and their caregivers. When patients approach the end of life, they are often faced with a challenging multidimensional burden while navigating a complex health care system. Patients and families/caregivers are faced with daily decisions, often with little or no frame of reference or medical knowledge. The "what, how, when, and where" puzzle during this challenging time can be overwhelming for patients and their families, and when clinicians do not contemplate this associated workload's impact on patients and caregivers' capacity for self-care, patients and caregivers scramble to find compensatory solutions, often putting their health care at lower priority...
March 13, 2018: Curēus
https://www.readbyqxmd.com/read/29753129/applications-of-rna-indexes-for-precision-oncology-in-breast-cancer
#6
REVIEW
Liming Ma, Zirui Liang, Hui Zhou, Lianghu Qu
Precision oncology aims to offer the most appropriate treatments to cancer patients mainly based on their individual genetic information. Genomics has provided numerous valuable data on driver mutations and risk loci; however, it remains a formidable challenge to transform these data into therapeutic agents. Transcriptomics describes the multifarious expression patterns of both mRNAs and non-coding RNAs (ncRNAs), which facilitates the deciphering of genomic codes. In this review, we take breast cancer as an example to demonstrate the applications of these rich RNA resources in precision medicine exploration...
May 9, 2018: Genomics, Proteomics & Bioinformatics
https://www.readbyqxmd.com/read/29745843/hierarchical-structural-component-modeling-of-microrna-mrna-integration-analysis
#7
Yongkang Kim, Sungyoung Lee, Sungkyoung Choi, Jin-Young Jang, Taesung Park
BACKGROUND: Identification of multi-markers is one of the most challenging issues in personalized medicine era. Nowadays, many different types of omics data are generated from the same subject. Although many methods endeavor to identify candidate markers, for each type of omics data, few or none can facilitate such identification. RESULTS: It is well known that microRNAs affect phenotypes only indirectly, through regulating mRNA expression and/or protein translation...
May 8, 2018: BMC Bioinformatics
https://www.readbyqxmd.com/read/29744965/mind-body-interventions-for-fear-of-cancer-recurrence-a-systematic-review-and-meta-analysis
#8
REVIEW
Daniel L Hall, Christina M Luberto, Lisa L Philpotts, Rhayun Song, Elyse R Park, Gloria Y Yeh
OBJECTIVE: Fear of cancer recurrence (FCR) is a common existential concern and source of distress among adults with a cancer history. Multiple randomized controlled trials (RCTs) have examined mind-body approaches to mitigating FCR. We summarized characteristics of these trials and calculated their pooled effects on decreasing FCR. METHODS: Six electronic databases were systematically searched from inception to May 2017, using a strategy that included multiple terms for RCTs, cancer, mind-body medicine, and FCR...
May 10, 2018: Psycho-oncology
https://www.readbyqxmd.com/read/29744615/systems-biology-systems-medicine-systems-pharmacology-the-what-and-the-why
#9
Angélique Stéphanou, Eric Fanchon, Pasquale F Innominato, Annabelle Ballesta
Systems biology is today such a widespread discipline that it becomes difficult to propose a clear definition of what it really is. For some, it remains restricted to the genomic field. For many, it designates the integrated approach or the corpus of computational methods employed to handle the vast amount of biological or medical data and investigate the complexity of the living. Although defining systems biology might be difficult, on the other hand its purpose is clear: systems biology, with its emerging subfields systems medicine and systems pharmacology, clearly aims at making sense of complex observations/experimental and clinical datasets to improve our understanding of diseases and their treatments without putting aside the context in which they appear and develop...
May 9, 2018: Acta Biotheoretica
https://www.readbyqxmd.com/read/29743054/australian-integrative-oncology-services-a-mixed-method-study-exploring-the-views-of-cancer-survivors
#10
Jennifer Hunter, Jane Ussher, Chloe Parton, Andrew Kellett, Caroline Smith, Geoff Delaney, Eleanor Oyston
BACKGROUND: The significant use of traditional and complementary medicine (T&CM) by cancer survivors is well documented. The aim of this study was to explore cancer survivors' views on integrating T&CM services with conventional cancer care. METHOD: A mixed-method study design with an emphasis on qualitative methodology was used to conduct and analyse four focus group interviews and an on-line survey. Purposive sampling recruited 33 cancer survivors and caregivers from Arabic, Vietnamese, Chinese and Anglo-European Australian backgrounds who participated in one of four focus group interviews, and 121 cancer survivors who responded to an on-line survey...
May 9, 2018: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/29743048/clinical-decision-making-in-cancer-care-a-review-of-current-and-future-roles-of-patient-age
#11
Eirik Joakim Tranvåg, Ole Frithjof Norheim, Trygve Ottersen
BACKGROUND: Patient age is among the most controversial patient characteristics in clinical decision making. In personalized cancer medicine it is important to understand how individual characteristics do affect practice and how to appropriately incorporate such factors into decision making. Some argue that using age in decision making is unethical, and how patient age should guide cancer care is unsettled. This article provides an overview of the use of age in clinical decision making and discusses how age can be relevant in the context of personalized medicine...
May 9, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29742928/an-integrated-study-on-the-antitumor-effect-and-mechanism-of-triphala-against-gynecological-cancers-based-on-network-pharmacological-prediction-and-in-vitro-experimental-validation
#12
Yuhang Zhao, Min Wang, Jokyab Tsering, Hanluo Li, Simin Li, Yuepeng Li, Yinghua Liu, Xianda Hu
OBJECTIVES: Triphala is a herbal medicine that has been widely used for treating a variety of ailments. This study aims to systematically analyze the antitumor effects of Triphala on gynecological cancers. METHODS: The antineoplastic activities of Triphala on gynecological cancers were analyzed using network pharmacology-based strategies. Afterward, the human ovarian cancer cell line SK-OV-3, cervical cancer cell line HeLa, and endometrial cancer cell line HEC-1-B were selected for experimetal valification...
May 1, 2018: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/29738578/cancer-driver-mutation-prediction-through-bayesian-integration-of-multi-omic-data
#13
Zixing Wang, Kwok-Shing Ng, Tenghui Chen, Tae-Beom Kim, Fang Wang, Kenna Shaw, Kenneth L Scott, Funda Meric-Bernstam, Gordon B Mills, Ken Chen
Identification of cancer driver mutations is critical for advancing cancer research and personalized medicine. Due to inter-tumor genetic heterogeneity, many driver mutations occur at low frequencies, which make it challenging to distinguish them from passenger mutations. Here, we show that a novel Bayesian hierarchical modeling approach, named rDriver can achieve enhanced prediction accuracy by identifying mutations that not only have high functional impact scores but also are associated with systemic variation in gene expression levels...
2018: PloS One
https://www.readbyqxmd.com/read/29737231/progressive-tissue-biomarker-profiling-in-non-muscle-invasive-bladder-cancer
#14
David D'Andrea, Melanie R Hassler, Mohammad Abufaraj, Francesco Soria, Iris E Ertl, Dafina Ilijazi, Andrea Mari, Beat Foerster, Gerda Egger, Shahrokh F Shariat
The recurrence rate of non-muscle-invasive bladder cancer (NMIBC) is up to 60% within the first year of therapy. Accurate risk stratification is necessary for patient counselling, follow-up scheduling and individualized therapeutic decision making. Current prognostic models rely on clinicopathologic features, but their discrimination remains limited when in external cohorts. Despite intense efforts regarding the value of biomarkers in prognosticating outcomes in NMIBC, clinical utility remains suboptimal. It is clear that a single biomarker is not enough for the prediction of disease recurrence...
May 9, 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29736721/a-quantitative-systems-pharmacology-approach-to-infer-pathways-involved-in-complex-disease-phenotypes
#15
Mark E Schurdak, Fen Pei, Timothy R Lezon, Diane Carlisle, Robert Friedlander, D Lansing Taylor, Andrew M Stern
Designing effective therapeutic strategies for complex diseases such as cancer and neurodegeneration that involve tissue context-specific interactions among multiple gene products presents a major challenge for precision medicine. Safe and selective pharmacological modulation of individual molecular entities associated with a disease often fails to provide efficacy in the clinic. Thus, development of optimized therapeutic strategies for individual patients with complex diseases requires a more comprehensive, systems-level understanding of disease progression...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29735382/evidence-based-nonpharmacologic-strategies-for-comprehensive-pain-care-the-consortium-pain-task-force-white-paper
#16
Heather Tick, Arya Nielsen, Kenneth R Pelletier, Robert Bonakdar, Samantha Simmons, Ronald Glick, Emily Ratner, Russell L Lemmon, Peter Wayne, Veronica Zador
Consortium Pain Taskforce White Paper Summary Evidence-based Nonpharmacologic Strategies for Comprehensive Pain Care Supplementary information can be found in the online version at https://doi.org/10.1016/j.explore.2018.02.001. Medical pain management is in crisis; from the pervasiveness of pain to inadequate pain treatment, from the escalation of prescription opioids to an epidemic in addiction, diversion and overdose deaths. The rising costs of pain care and managing adverse effects of that care have prompted action from state and federal agencies including the DOD, VHA, NIH, FDA and CDC...
March 1, 2018: Explore: the Journal of Science and Healing
https://www.readbyqxmd.com/read/29733728/strategies-for-clinical-implementation-precision-oncology-at-three-distinct-institutions
#17
Lincoln D Nadauld, James M Ford, Daryl Pritchard, Thomas Brown
Despite rapid advances in molecular diagnostics and targeted therapeutics, the adoption of precision medicine into clinical oncology workflows has been slow. Questions about clinical utility, inconsistent reimbursement for molecular diagnostics, and limited access to targeted therapies are some of the major hurdles that have hampered clinical adoption. Despite these challenges, providers have invested in precision medicine programs in an ongoing search for innovative care models to deliver improved patient outcomes and achieve economic gains...
May 2018: Health Affairs
https://www.readbyqxmd.com/read/29732534/epigenetic-loss-of-heparan-sulfate-3-o-sulfation-sensitizes-ovarian-carcinoma-to-oncogenic-signals-and-predicts-prognosis
#18
Rui-Lan Huang, Hsiang-Ju Chen, Lin-Yu Chen, Tai-Kuang Chao, Wei-Yu Lin, Phui-Ly Liew, Po-Hsuan Su, Yu-Chun Weng, Yu-Chi Wang, Chi-Chun Liao, Yaw-Wen Hsu, Hui- Chen Wang, Hung-Cheng Lai
Precision medicine requires markers for therapeutic guidance. The purpose of this study was to determine whether epithelial ovarian cancer (EOC) epigenetics can lead to the identification of biomarkers for precision medicine. Through integrative methylomics, we discovered and validated the epigenetic signature of NEFH and HS3ST2 as an independent prognostic factor for type II EOC in our dataset (n = 84), two independent methylomics datasets (total n = 467). Integrated transcriptomics dataset (n = 1147) and tissue microarrays (n = 54) of HS3ST2 also related to high-methylation statuses and the EOC prognosis...
May 7, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29728019/-molecular-mechanism-of-mylabris-for-colorectal-cancer-based-on-integrative-pharmacology
#19
Lei Yang, Meng-Jiao Liu, Zhi-Guo Zhang, Wen-Ming Chen, Qin Zhang, Lin Ouyang, Ping Wu
At present, the disjointing situation is generally present between "systemic"and "local", "macro" and "micro", " in vivo process" and "activity evaluation" in the study of traditional Chinese medicine (TCM). An urgent task for the modernization of TCM is to establish new strategies and methods which can reflect the overall characteristics of TCM. The introduction of integrative pharmacology provided a feasible approach to solve the problem of the fragmentation of TCM...
April 2018: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://www.readbyqxmd.com/read/29727544/-clinical-efficacy-of-integrated-traditional-chinese-and-western-medicine-for-castration-resistant-prostate-cancer
#20
Yang Zhang, Bo-Han Lei, Qing Zou, Qing-Yi Zhu, Zi-Jie Lu, Yue Wang
Objective: To investigate the clinical effects of integrated traditional Chinese and Western medicine in the treatment of castration-resistant prostate cancer (CRPC). METHODS: A total of 54 CRPC patients were randomly divided into a control and a trial group, all treated by endocrine therapy (oral Bicalutamide at 50 mg per d plus subcutaneous injection of Goserelin at 3.6 mg once every 4 wk) and chemotherapy (intravenous injection of Docetaxel at 75 mg/m2 once every 3 wk plus oral Prednisone at 5 mg bid), while the latter group by Fuyang Huayu Prescription (a Traditional Chinese Medicine [TCM] prescription for tonifying yang and dispersing blood stasis) in addition, for a course of 24 weeks...
October 2017: Zhonghua Nan Ke Xue, National Journal of Andrology
keyword
keyword
112721
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"